Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human KCNJ5 Antibodies:
anti-Mouse (Murine) KCNJ5 Antibodies:
anti-Rat (Rattus) KCNJ5 Antibodies:
Go to our pre-filtered search.
Human Polyclonal KCNJ5 Primary Antibody for IHC, IHC (p) - ABIN4329042
Azizan, Poulsen, Tuluc, Zhou, Clausen, Lieb, Maniero, Garg, Bochukova, Zhao, Shaikh, Brighton, Teo, Davenport, Dekkers, Tops, Küsters, Ceral, Yeo, Neogi, McFarlane, Rosenfeld, Marass, Hadfield et al.: Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. ... in Nature genetics 2013
Show all 2 Pubmed References
Human Polyclonal KCNJ5 Primary Antibody for WB - ABIN1944847
Olsen, Blagoev, Gnad, Macek, Kumar, Mortensen, Mann: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. in Cell 2006
Show all 2 Pubmed References
Human Polyclonal KCNJ5 Primary Antibody for WB - ABIN1881206
Maita, Kitaura, Ariga, Iguchi-Ariga: CIR, a corepressor of CBF1, binds to PAP-1 and effects alternative splicing. in Experimental cell research 2005
Show all 2 Pubmed References
rs2604204 polymorphism related to increased plasma aldosterone level, but also plasma renin (show REN Antibodies), angiotensin I and II levels in newly diagnosed, never-treated hypertension patients
our results provide evidence that during 12 months of follow-up of APA (show ENPEP Antibodies) patients after adrenalectomy, KCNJ5 mutational status was not associated with the improvement of arterial stiffness. Clinically, patients who are younger tend to have an advantage in being cured of hypertension after adrenalectomy.
An aldosterone-driving KCNJ5 mutation was detected in juvenile primary aldosteronism, but not in the histologically normal cortex.
By proving the principle that the oversecretion of aldosterone can be specifically blunted in APA (show ENPEP Antibodies) cells ex vivo with G151R and L168R mutations, these results provide compelling evidence of the possibility of specifically correcting aldosterone excess in patients with APA (show ENPEP Antibodies) carrying the 2 most common KCNJ5 somatic mutations.
KCNJ5(T158A)increases CYP11B2 (show CYP11B2 Antibodies) expression and production of aldosterone, corticosterone and hybrid steroids by upregulating both acute and chronic regulatory events in aldosterone production, and verapamil blocks KCNJ5(T158A)-mediated pathways leading to aldosterone production.
These findings expand on the clinical spectrum of phenotypes associated with KCNJ5 mutations and implicate these mutations in the pathogenesis of hypertension associated with increased aldosterone response to ACTH (show POMC Antibodies) stimulation.
KCNJ5 mutations predominate in large zona fasciculata (ZF)-like Aldosterone-producing Adenomas.
Mutations in KCNJ5 cause the excessive autonomous aldosterone secretion of Aldosterone-producing Adenomas.
KCNJ5 genetic mutation plays a role in the development of primary aldosteronism in aldosterone producing adenomas.
Study provides new evidence, indicating that some glutamate receptor ionotropic kainate 4 (show GRIK4 Antibodies) variants modulate the response to electroconvulsive therapy in patients with depression resistant to treatment, suggesting a role for kainate receptor modulation.
histone H4 (show HIST1H4H Antibodies) hyperacetylation induced by Class I HDACs inhibitors promoted the expression profiles of potassium channels (Kcnj2 (show KCNJ2 Antibodies), Kcnj3 (show KCNJ3 Antibodies), Kcnj5, Kcnj11 (show KCNJ11 Antibodies), and Kcnh2 (show KCNH2 Antibodies))
These results provide a novel molecular mechanism for autocrine negative feedback regulation of insulin (show INS Antibodies) secretion.
study establishes the role of f-channels in cardiac automaticity and indicates that arrhythmia related to HCN loss-of-function may be managed by pharmacological or genetic inhibition of GIRK4 channels
Data indicate taht m2R-RGS6 (show RGS6 Antibodies)-IKACh pathway sets heart rate variability independently from the autonomic input.
Therefore, the lack of proper functioning of the cardio-protective K(ATP) system in the mdx (show DMD Antibodies) cardiomyocytes may be part of the mechanism contributing to development of cardiac disease in dystrophic patients.
Data suggest HL-1 (show ASGR1 Antibodies) cells express GIRK1 (show KCNJ3 Antibodies)/4 and M2 muscarinic receptors and are a good model to study acetylcholine-activated potassium currents.
Data show that the composition of the Kir3.1 (show KCNJ3 Antibodies) and Kir (show GEM Antibodies) 3.4 subunits of the G protein-gated potassium channel (show KCNAB2 Antibodies) changes during embryonic development.
These data implicate GIRK4-containing channels in signaling crucial to energy homeostasis and body weight.
Blockade of K(ATP) channels further diminished (approximately 45%) the repayment of flow debt (show PLXNB2 Antibodies) in lean but not metabolic syndrome swine.
Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein, which has a greater tendency to allow potassium to flow into a cell rather than out of a cell, is controlled by G-proteins. It may associate with two other G-protein-activated potassium channels to form a heteromultimeric pore-forming complex.
G protein-activated inward rectifier potassium channel 4
, cardiac ATP-sensitive potassium channel
, heart KATP channel
, inward rectifier K+ channel KIR3.4
, cardiac inward rectifier
, inward rectifier K(+) channel Kir3.4
, potassium channel, inwardly rectifying subfamily J member 5
, inward rectifying K channel
, potassium inwardly-rectifying channel J5
, Cardiac inward rectifier
, Heart KATP channel
, Inward rectifier K(+) channel Kir3.4
, Potassium channel, inwardly rectifying subfamily J member 5
, potassium inwardly-rectifying channel, subfamily J, member 5